Rouba Residency Personal Statement

Larry Greenbaum, MD, PhD
Division Director
Donald Batisky, MD
Director, Pediatric Hypertension Program
Stella Shin, MD
Assistant Professor
Rouba Garro, MD
Assistant Professor
Medical Director of Kidney Transplant
Stephanie Jernigan, MD
Assistant Professor
Chief of Medicine Service Line
Medical Director of Dialysis
Chia-shi Wang, MD, MSc
Assistant Professor
Roshan George, MD
Assistant Professor
Associate Pediatric Nephrology Fellowship Program Director
Director of Renal Transplant Transition Program
Director, Transplant Quality
Sabina Kennedy, MD
Assistant Professor
Barry Warshaw, MD
Fellowship Program Director
Pamela Winterberg, MD
Assistant Professor
To apply for a Fellowship, please complete an application through the Electronic Residency Application System (ERAS).

In order to be considered, applicants must have completed an accredited three-year pediatric residency program from U.S. or Canadian Institution by the beginning of the Fellowship program.

A completed application file will include:

  1. Completed application submitted through ERAS
  2. Current curriculum vitae
  3. Personal statement (The personal statement should include a description of previous research and clinical experience, reason for interest in a Pediatric Nephrology Fellowship, and an indication of your career goals.)
  4. Three letters of reference. One letter should be from the Director of your Residency Training Program
  5. USMLE Steps 1, 2, and 3 Score Reports
  6. Official Medical School Transcript
  7. ECFMG Report, if applicable
  8. A recent photograph (optional)

Interviews are required and will be conducted from September through November. Applicant selection will be done through the National Resident Matching Program (NRMP).

Relevant dates for applicants for 2017 are as follows:
  • July 6, 2017: Applicants may apply to program through ERAS.
  • July 15, 2017: ERAS opens to program for application down loading.
  • October 25, 2017: NRMP Rank order list opens.
  • November 29, 2017: NRMP Rank order list closes.
  • December 13, 2017: Match Day.


The first year of training is dedicated primarily to clinical activities and the second and third years primarily to research, comprising a total of 16 months clinical emphasis and 20 months research. Abundant didactic activities and conferences, as described below, including a formal histopathology course taken with the adult nephrology fellows, provide for a rich learning environment.

FIRST YEAR: The first year of the program is dedicated primarily to clinical training, comprising 10 months, with 2 months allocated to introduction to research. Clinical training includes assignments to the inpatient wards and involves experience managing a wide variety of patients assigned to the nephrology service with disorders such as new and relapsing nephrotic syndrome, acute and chronic glomerulonephritis, hypertension, acute and chronic renal failure, hemolytic-uremic syndrome, new renal transplant recipients and those experiencing complications, and both peritoneal and hemodialysis patients. Fellows learn skills including renal biopsy and ordering of dialysis. During inpatient ward assignments, fellows also provide consultation to other services including the ICU's (PICU, NICU, and CICU) and learn to manage all acute dialysis modalities (hemodialysis, PD, and a high volume of continuous renal replacement predominantly in the form of CVVH). Advanced knowledge of fluid and electrolyte management is taught during these inpatient and consult service rotations. Six weeks of the first year entails full time assignment to our pediatric-specific hemodialysis unit and peritoneal dialysis clinic, a partnership with DaVita Dialysis, wherein fellows have in-depth training in principles, literature, and application of dialysis as well as the opportunity for hands-on familiarity with hemodialysis & peritoneal dialysis equipment & techniques. Similarly, in the ICUs, fellows learn the details of CVVH and are afforded hands-on familiarity with CVVH equipment and setup.

Two months of the first year are dedicated to research orientation with initial opportunity for project selection. In addition, Fellows participate in formal department-wide fellowship courses in Research Fundamentals, Quality Improvement, and Medical Ethics.

SECOND YEAR: The second year begins with consecutive research months during which the fellow finalizes selection of research project(s) and mentor(s). Two months are dedicated to inpatient ward assignments, and additional time is allocated to a mixture of important clinical experiences including coursework with Dr. Charles O'Neill in the Emory Department of Medicine Division of Nephrology learning Ultrasound for the Nephrologist; this course is virtually unique in the country and one that numerous practicing nephrologists have taken with excellent reviews; observations in the Emory HLA lab and with our local organ procurement organization (Lifelink); and experience with our Pediatric Urology colleagues observing voiding dysfunction clinics, urodynamic studies, and other relevant activities. Second year fellows participate in a formal department-wide fellowship course in Teaching to Teach. During clinical assignments in the second and third years, the Fellow assumes increased responsibilities in the evaluation and care of patients and in teaching of pediatric residents and medical students.

THIRD YEAR: The third year of training is dedicated primarily to completion of research projects and writing related abstracts and manuscripts. Two months of this year are spent on the inpatient wards with advanced clinical responsibilities.

During the entire 3-year training period, fellows attend all section conferences and seminars plus they are afforded the responsibility to follow their own cohort of general Nephrology patients in a mentored Fellows’ Continuity Clinic.

WEEKEND/NIGHT CALL: Fellows take weekend call averaging one weekend every fifth week throughout the 3 year training period. Weeknight call averages every fourth or fifth night. Night call is always taken from home. An attending pediatric nephrologist is always on call with the Fellow. Fellows on call round with the attending on the inpatient service during weekends and holidays. Fellows average at least 3 two-day weekends off every 4 weeks. If circumstances arise, the Fellow will be dismissed home from inpatient clinical responsibilities to conform to the 80 hour per week maximum, in keeping with ACGME guidelines. Fellows are entitled to 3 weeks of vacation per year that may be taken at any time during research or outpatient rotation months with approval of the Program Director.

ADVOCACY: Each fellow is given the opportunity to attend Camp Independence. Hosted by Children’s Healthcare of Atlanta, Camp Independence is one of the oldest and largest camps in the country for children and adolescents who have been diagnosed with kidney disease, are on dialysis, or have received a solid organ transplant. Camp Independence is a week-long summer camp experience held at Camp Twin Lakes, a unique camp venue that provides year-round recreational, therapeutic and educational programs for children facing serious illnesses and life challenges. For more information about Camp Independence, go to

Pediatric Nephrology Renal Pathology Conference

Frequency: Monthly

This is a case-based conference with case presentations by nephrology faculty and/or Fellows followed by presentation of histologic findings in a teaching format presented by our pediatric renal pathologists.

Practical Nephropathology for Nephrology Fellows:

This is an annual focused renal pathology course for Adult and Pediatric Nephrology Fellows conducted by Emory renal pathologist Dr. Brad Farris and colleagues. The course comprises 8 hours of didactic presentations and covers at least the following topics:

       Normal Histology of the Kidney
       Immune Mechanisms of Glomerular Pathology
       Minimal Change Disease-Focal Sclerosis
       Membranous Nephropathy
       Membranoproliferative Glomerulonephritis
       IgA Nephropathy
       Acute Post-Streptococcal Glomerulonephritis
       Crescentic Glomerulonephritis
       Lupus Nephritis
       Diabetic Nephropathy
       Thrombotic Microangiopathy
       Renal Transplant Pathology

Pediatric Nephrology Journal Club

Frequency: Monthly

Fellows and faculty present and discuss recently published articles of importance.

Pediatric Nephrology Invitee Conference

Frequency: Monthly

Topics of nephrologic interest are selected to be presented by Divisional faculty, local faculty or Fellow invitees, or Pediatric Nephrology Fellows (once yearly in their 2nd and 3rd years).

Pediatric Nephrology Core Curriculum Course

Frequency: Monthly

Fellows and faculty present didactic reviews of the core topics in the fellowship curriculum. There are 33 topics that are covered during the 3 year fellowship. In addition, 10 core Orientation topics are presented in a concentrated fashion each year during the month of July.

Pediatric Departmental CPC Grand Rounds

Frequency: Weekly

Departmental CPC Grand Rounds are presented by a Pediatric Resident and moderated by a pediatric faculty member with audience interaction, followed by a didactic wrap-up of the case-in-point by a faculty member or Fellow. Nephrology Fellows are expected to provide the didactic discussion at least once during their 2nd or 3rd year.

Emory Transplant Conference

Frequency: Weekly from September through May

These are outstanding didactic conferences presented by local faculty and distinguished worldwide guest speakers.

Emory Adult Nephrology Grand Rounds

Frequency: Weekly

These are outstanding didactic conferences presented by local faculty and fellows and distinguished worldwide guest speakers.

Multidisciplinary Pediatric Renal Transplant Patient Care Conference

Frequency: Monthly

Chronic kidney disease patients undergoing evaluation for renal transplantation are discussed to identify issues affecting eligibility for or special needs regarding transplantation in participatory fashion by pediatric nephrology faculty, Fellows, transplant surgeons, transplant nurse coordinators, social workers, and others.

Research in Progress Seminar

Frequency: PRN

Fellows and faculty present proposed research projects, updates on ongoing research projects, or give practice presentations in preparation for scientific meetings.

Multidisciplinary Inpatient Care Rounds

Frequency: Daily (during in-patient rotations)

During inpatient coverage, the Fellow, under the close supervision of the pediatric nephrology attending, is responsible to coordinate care of inpatients and to involve team members in the discussion on daily rounds. Attendants include the pediatric resident (PL2 or PL3) on monthly assignment to the Nephrology service, medical students, transplant nurse coordinators, dialysis nurses, nurse practitioners, social workers, child-life specialist, nutritionist, pharmacist, transplant services chaplain, and case coordinator.

Multidisciplinary Patient Care Dialysis Conference

Frequency: Monthly

The plan of care for all pediatric hemodialysis and peritoneal dialysis patients is discussed, including medical management and preparation for kidney transplantation.


In addition to clinical training, fellows pursue mentored research across a wide variety of investigational choices. The area of concentration is selected based on the interest of the fellow who is responsible for designing, implementing, and completing a hypothesis-driven scholarly project under the guidance of a Scholarship Oversight Committee (SOC) of advisors and mentors. Fellows are encouraged, but are not required, to apply for and secure external funding for their research endeavors, and are expected to submit the results of their research for dissemination in appropriate scholarly venues.

All Emory first year fellows across the Department of Pediatrics participate in a focused introductory research course entitled Fellows Introduction to Research Training (FIRsT), directed by Dr. Inci Yildirim from our Division of Infectious Diseases and involving numerous Emory faculty teaching a wide spectrum of clinical research skills.  

A funded Masters of Science in Clinical Research (MSCR) degree program is available to selected fellows desiring the highest level of preparation for a career in clinical and/or translational research. (see:

An excellent Biostatistics Core provides assistance with analytics and statistical methodology for the design and preparation of studies, grant proposals, and manuscripts. (See

Division of Nephrology Fellows and Faculty alike benefit from outstanding clinical research coordinator support, led by Margo Kamel, PhD and a team of 3 other coordinators.  This group provides support for an impressive divisional portfolio of single and multicenter clinical research projects (see:

Research opportunities are diverse and plentiful (see Historical list of fellows’ projects below) and may include collaboration with investigators from other divisions, departments, or schools within Emory.

Primary Research projects completed, or underway, by Emory Pediatric Nephrology Fellows, and their Primary Mentors:

  • Jennifer Jackson MD (2007-10):  Urinary Chemokines CXCL9 and CXCL10 are Non-Invasive Markers of Renal Allograft Rejection and BK Viral Infection. Allan Kirk, MD, PhD, Dept of Surgery, Transplant Immunology
  • Raed Bou-Matar MD (2009-12: Protein Abundance of Urea Transporters and Aquaporin 2 Change Differently in Nephrotic Pair-fed vs. Non-pair-fed Rats. Janet Klein, PhD, Dept of Medicine, Nephrology.
  • Sandeep Riar MD (2009-12):  Restless Legs Syndrome: Severity, Iron Status & Inflammation in Pediatric Chronic Kidney Disease.  Larry Greenbaum MD, PhD, Division Director, Pediatric Nephrology
  • Roshan George MD (2010-13): T cell Senescence and Exhaustion in Pediatric Pre-Transplant Patients with Chronic Kidney Disease.  Allan Kirk, MD, PhD.  Dept of Surgery, Transplant Immunology
  • Shahid Nadeem MD (2011-14): ACE Fetopathy and A Randomized Study of Two Doses of Vitamin D in Children with CKD.  Larry Greenbaum, MD, PhD.  Division Director, Pediatric Nephrology
  • Chia-shi Wang MD (2012-15): Single Center Experience of Inpatient Healthcare Utilization Among Pediatric Patients with Nephrotic Syndrome.  Larry Greenbaum, MD, PhD.  Division Director, Pediatric Nephrology
  • Frank Ayestaran MD (2012-15): Perceived Appetite and Clinical Outcomes in Children with Chronic Kidney Disease.  Larry Greenbaum, MD, PhD.  Division Director, Pediatric Nephrology
  • Rima Zahr DO (2013-16): Renoprotection by Atorvastatin in Sickle Cell Disease and A Multicenter Study of Biopsy Findings and Clinical Outcomes in Children with Sickle Cell Disease.  David Archer, PhD.  Pediatric Hematology and Larry Greenbaum, MD, PhD. Division Director, Pediatric Nephrology
  • Alana Bozeman MD (2014-17): Profiling Metabolic Differences between Graft- vs. Pathogen-Elicited CD8+ T Cell Responses.  Mandy Ford, PhD, Dept of Surgery, Transplant Immunology
  • Loretta Reyes MD (2015- ): Role of Dysregulated Arginine Metabolism in Uremic Cardiomyopathy.  Claudia Morris, MD.  Pediatric Emergency Medicine.
  • K’joy Simms MD (2106- ): Perceptions of Patients with Polycystic Kidney Disease on the Risk for Affected Offspring.  Fred Rhabari, MD.  Dept of Medicine, Nephrology
  • Karie Mersha MD (2016- ): Transplant Outcomes of Young Adults Cared for at Adult vs Pediatric Transplant Centers.  Rachel Patzer, PhD, MPH.  Dept of Surgery, Transplant Outcomes Research Program


PGY-6 Fellow
Loretta Reyes, MD
Medical School: St. George’s University School of Medicine, Grenada
Residency: Driscoll Children’s Hospital, Corpus Christi, TX
PGY-5 Fellows
Karezhe Mersha, MD
Medical School: University of Maryland, Baltimore, MD
Residency: University of Maryland Medical Center, Baltimore, MD
PGY-5 Fellows
K’joy Simms, MD
Medical School: University of the West Indies Faculty of Medical Sciences, Jamaica
Residency: Morehouse School of Medicine, Atlanta, GA
PGY-4 Fellows
Jackson Londeree, DO
Medical School: Arizona College of Osteopathic Medicine of Midwestern University
Residency/Chief Residency: The University of Texas Dell Medical School. Austin, TX
PGY-4 Fellows
Catherine Park, MD
Medical School: Medical College of Georgia at Augusta University, Augusta, GA
Residency/Chief Residency: University of Tennessee Health Science Center, Memphis, TN

1. Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome: ATLANTIS Study

Purpose: In childhood nephrotic syndrome, the kidneys leak protein, causing body swelling and a variety of possible complications such as infection, blood clots, and kidney failure. The firstline treatment for nephrotic syndrome is corticosteroids. Many children respond to prednisone treatment, but the disease comes back (relapses) when the prednisone is stopped or the dose is reduced. Children with frequently relapsing or steroid dependent nephrotic syndrome are at risk for toxicity from frequent exposure to corticosteroids.

Currently, the standard treatment for frequently relapsing and steroid dependent nephrotic syndrome involves a variety of medications that suppress the immune system, which can produce serious side effects. We propose a study to examine the effects of a different medication, ACTH, on nephrotic syndrome. ACTH is a hormone naturally found in the body. Recently, in adult studies, ACTH has been shown to be effective for the treatment of nephrotic syndrome. It has also been shown to have mild and reversible side effects. ACTH is potentially an attractive therapeutic alternative for the treatment of frequently relapsing and steroid dependent nephrotic syndrome in children. Our study will randomly assign patients with frequently relapsing or steroid dependent nephrotic syndrome to either ACTH treatment or no treatment. This will allow us to study the effects of ACTH on this disease and its side effects, by comparing how patients do on ACTH treatment versus no treatment. We hypothesize that ACTH gel is superior to no treatment in maintaining remission in children with frequently relapsing or steroid dependent nephrotic syndrome.

Recruitment status: Enrolling

Sponsor: Mallinckrodt Pharmaceuticals

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA and Dr. Chia-shi Wang, Assistant Professor, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Study coordinator: Margo Kamel, PhD

2. An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients with Atypical Hemolytic-Uremic Syndrome (aHUS Registry) (Study Number: M11- 001)

Purpose: The registry is an observational, non-interventional, multi-center, multi-national, study that has been designed to capture safety and effectiveness data specific to the use of eculizumab in aHUS patients, as well as to compile data on the long term manifestations of TMA complications of aHUS. The registry will enroll aHUS patients treated not with eculizumab. It is anticipated that patients will be followed at least for 5 years. Data collected in the registry will be reported to the FDA and the EMA.

Recruitment status: open to enrollment

Sponsor: Alexion Pharmaceuticals

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Ling Iem, BS

3. Evaluation of Potential Predictors of Disease Progression in Patients with aHUS, Including Genetics, Biomarkers, and Treatment (EVIDENCE) (STUDY Number: ECUaHUS-403)

Purpose: This is a prospective, open-label study with no patient randomization. Treatment for atypical hemolytic uremic syndrome (aHUS) will remain observational and at the discretion of the treating physician. The purpose of this study is to assess disease manifestations of complement mediated thrombotic microangiopathy (TMA) and potential clinical predictors of disease manifestations and progression in patients with aHUS with or without eculizumab treatment in the clinical setting.

Recruitment Status: Enrolling

Sponsor: Alexion Pharmaceuticals

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Ling Iem, BS

4. Chronic Kidney Disease in Children Prospective Cohort Study (CKiD III)

Purpose: This is an observational study of children with chronic kidney disease. The primary goals of this study are to determine the risk factors for decline in kidney function and to define how a progressive decline in kidney function impacts neurocognitive function and behavior; the risk factors for cardiovascular disease; and growth failure and its associated morbidity.

Recruitment status: Enrolling

Sponsor: National Institute of Health (NIH)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Ling Iem, BS and Margo Kamel, PhD

5. Childhood Nephrotic Syndrome Observational Study (CNOS)

Purpose: Childhood onset nephrotic syndrome is a condition that affects the kidneys. It causes them to leak protein from the blood into the urine. The purpose of this study is to improve our understanding of the causes, effects, and treatment response of childhood nephrotic syndrome. We are also hoping to find out more information about how nephrotic syndrome progresses in different people and how or why that happens.

Recruitment status: Enrolling

Sponsor: Investigator Initiated

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Matthew Bennett, BS and Priscilla Quach, BS

6. Executive Function in Children with Hypertension

Purpose: Studies in young adults indicate that primary hypertension is associated with decreased performance on neurocognitive testing compared with normotensive controls, particularly in the domains of attention, working memory, and executive function. These cognitive deficits can improve in adults when hypertension is subsequently well-controlled, indicating that the neurocognitive deficits seen in hypertensives may represent an early manifestation of hypertensive target organ damage of the brain. The goal of the current proposal is to investigate the relationship between primary hypertension and executive function as an emerging target of hypertensive damage in children. The overall hypothesis is that children with primary hypertension have evidence for central nervous system target organ damage, as manifested by decreased executive function.

Recruitment status: closed to enrollment

Sponsor: NIH

Site PI: Dr. Donald Batisky, Director of Hypertension Program, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Brian Lee, BS

7. Immune Monitoring and Assay Development in Kidney Transplant Recipients (IMP)

Purpose: Currently, a kidney biopsy is the only way to determine whether a patient with a kidney transplant has rejection of their kidney. The goals of this study are to develop and study urine and blood tests that can determine if a patient is rejecting a transplanted kidney. This will hopefully decrease the need to perform kidney biopsies and allow for earlier diagnosis of rejection.

Recruitment Status: Enrolling

Sponsor: Investigator Initiated

Sponsor: PIs: Dr. Roshan George and Dr. Pamela Winterberg, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Brian Lee, BS

8. A Molecular Pathogenesis-Driven Approach for Diagnosis and Treatment of Complement-Based Renal Diseases (KidCOM)

Purpose: The purpose of this research is to build a registry of patients with aHUS and MPGN. MPGN is a rare disease that can cause problems with how the kidney filters blood and waste. Currently, little is known about how to treat MPGN. There are three different types of MPGN; MPGN I, MPGN II/Dense Deposit Disease (MPGN II/DDD), and MPGN III. Although we will look at all types of MPGN, we are focused on MPGN II/DDD because it is most closely linked to the immune system. Hemolytic Uremic Syndrome (HUS) is another rare immune disease that affects blood supply to the kidneys, and impairs their function. There are two types of HUS; typical HUS, and atypical HUS. Typical HUS, which is usually diagnosed in childhood, is due to a bacterial infection in the stomach and intestines. Atypical HUS (aHUS) is a hereditary disease that is associated with recurrent episodes.

Recruitment status: Enrolling

Collaborators: Dr. Christoph Licht at The Hospital for Sick Children, Toronto, Ontario, Canada; Dr. William Smoyer at The Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Dr. Patrick Brophy at University of Iowa Hospitals and Clinics, Iowa City, Iowa.

Sponsors: Foundation for Children with Atypical HUS, and Optherion, Inc.

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Brian Lee, BS

9. Pediatric Lupus Nephritis Registry (Lupus Registry)

Purpose: This study will examine the incidence, causes, clinical course, and outcomes in children with lupus kidney disease. After informed consent and assent, medical records will be reviewed and history, physical exam findings, laboratory, radiology, hospital events, and medication information will be recorded into a multi-center registry. Longitudinal data will be collected for at least 5 years after entry into the registry.

Recruitment status: Enrolling

Participating site with Children’s Hospital of Chicago

Site PI: Dr. Donald Batisky, Director of Hypertension Program, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Brian Lee, BS

10. Nephrotic Syndrome Study Network (NEPTUNE)

Purpose: The purpose of this study is to find markers of Nephrotic Syndrome (kidney disease with too much protein in the urine). We are particularly interested in diseases called Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN). By collecting health information and laboratory samples, our goal is to learn more about these kidney diseases and find better ways to prevent and treat people with these kidney diseases.

Recruitment status: Enrolling

Sponsor: National Institutes of Health (NIH)-National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinators: Brian Lee, BS and Helina Iyob-Tessema, BS

11. A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms with Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change)

Purpose:The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). Candidates must have a prior kidney biopsy with either diagnosis. Another kidney biopsy will not be required as part of the study. Candidates must have failed or be intolerant of prior therapy for their kidney disease. The failed or intolerant therapy must include corticosteroids and at least one other drug. Candidates can be adults and children over the age of 6. Abatacept will be administered by venous infusion every 4 weeks.

Recruitment status: Enrolling

Sponsor: Bristol-Myers Squibb

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Brian Lee, BS

12. Bovine Serum Albumin-Related Membranous Nephropathy

Purpose: Bovine serum albumin (BSA) is one of the cow’s milk and beef proteins that can escape from the intestinal barrier and induce formation of anti-BSA antibodies. Modern day foods are subjected to a variety of processing conditions that may modify food proteins, and thus could change their digestion and allow their passage into the blood stream. This study will examine individuals with a diagnosis of idiopathic membranous nephropathy and investigate the involvement of cationic BSA and its relationship to the subject’s clinical presentation, past medical history including dietary history, family history, and clinical course.

Recruitment status: Enrolling

Sponsor: Investigator Initiated

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Brian Lee, BS

13. CureGN: Cure Glomerulonephropathy Network (CureGN)

Purpose: There are several different types of glomerular diseases, such as minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and immunoglobulin A nephropathy (IgAN). Over time, these diseases may cause kidney damage. These kidney diseases are rare and because of that, it is difficult for individual researchers to gather a large enough number of people to effectively study underlying causes, identify markers of disease, and identify and evaluate new therapies. The purpose of CureGN is to gather a group of patients with glomerular disease to create a source of information and blood and urine samples, so that researchers can easily and effectively study glomerular disease.

Recruitment Status: Enrolling

Sponsor: National Institute of Health (NIH)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Margo Kamel, PhD and Helina Iyob Tessema, BS

14. "A Phase 3b, Multicenter, Open-label, Randomized Withdrawal Trial of the Effects of Titrated Oral SAMSCA (Tolvaptan) on Serum Sodium, Pharmacokinetics, and Safety in Children and Adolescent Subjects Hospitalized With Euvolemic or Hypervolemic Hyponatremia" (OTSUKA)

Purpose: Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), is studying an investigational drug called tolvaptan (“Study Drug”). Tolvaptan (Samsca®) is a drug approved for use in the United States (2009) in patients with certain types of hyponatremia (low amount of sodium or salt in the blood) due to syndrome of inappropriate antidiuretic hormone. Tolvaptan (Samsca®) is approved in the European Union (2009) for treatment of a specific type of hyponatremia due to SIADH. Tolvaptan (Samsca®) has been approved by the Japanese Ministry of Health, Labour, and Welfare (2010) for the treatment of volume overload in heart failure when used in combination with other approved drugs.

Tolvaptan is still being studied to see if it can be used to treat problems associated with various causes of hyponatremia. A low amount of sodium in the blood may be due to abnormal hormone levels, medication that your child has to take, or another disease that your child may have. Low blood sodium levels may result in nausea, vomiting, and muscle discomfort. It may cause weakness and slow, abnormal, or poor thinking. Low blood sodium may cause abnormal behavior, seizures or fits, and coma or unconsciousness. It may cause lack of emotion or slowed breathing. Tests taken during the study will determine how useful tolvaptan will be in treating low blood sodium. The study doctor has determined that your child has low blood sodium levels. Your child is invited to take part in this research study.

The reason for this study is to find out the potential benefits and safety of tolvaptan in the pediatric and adolescent population. About 100 participants will be joining in this study globally or regionally in approximately 50 centers. It is expected that participation will last approximately 21 days for each participant.

Recruitment Status: Enrolling

Sponsor: Otsuka Pharmaceuticals

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Margo Kamel, PhD

15. A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)

Purpose: The objective of this trial is to provide 6 months of safety follow-up for children and adolescents with dilutional (euvolemic or hypervolemic) hyponatremia who have previously participated in a tolvaptan hyponatremia trial, and to assess the efficacy of tolvaptan in increasing serum sodium for those subjects who receive optional continuing tolvaptan treatment of variable duration (up to 6 months).

Recruitment Status: Not yet open to enrollment

Sponsor Otsuka Pharmaceuticals

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Margo Kamel, PhD

16. Amgen Study 20140159: A Multicenter Single-arm Extension Study to characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease on Dialysis. (Global Version 1.0)

Purpose: This is a phase 3, 32-week, multicenter, single arm, open-label extension study. All enrolled subjects will be administered cinacalcet daily during the treatment period in addition to standard of care treatment which can include therapy with Vitamin D sterols, calcium supplementation, and phosphate binders.

Recruitment Status: Enrollment closed

Sponsor: Amgen, Inc.

Site PI: Dr. Stephanie Jernigan, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site coordinator: Ling Iem, BS

17. LN Antibodies

Purpose: This study will examine the ability of novel antibodies or other biomarkers to predict 1) findings on kidney biopsy, 2) disease progression, or 3) response to therapy in children with lupus nephritis (LN). The intent is to enroll subjects who have or will also enroll in the MWPNC’s Pediatric LN Registry (however, involvement in the registry is not required). After obtaining informed consent and assent, medical records including history, exam findings, laboratory radiology and biopsy findings, treatment information, and outcomes will be prospectively reviewed and recorded. There are 2 levels of involvement for this study. The short term goal of this study will be to measure antibody titers against basement membrane (BM) antigens in the plasma and urine at onset of LN and again 6-mo into therapy. Results would be compared with the currently available clinical indicators of outcome and treatment response. The long-term goal of this study will be to establish a bio-repository of blood and urine samples (level 1) and kidney tissue (level 2) to assess the utility of additional autoantibodies or other biomarkers in MWPNC pediatric LN cohort, and to facilitate collaboration with larger efforts for biomarker identification in SLE that would otherwise not have access to pediatric samples.

Recruitment Status: Enrolling

Participating site with Midwest Pediatric Nephrology Consortium (MWPNC)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Brian Lee, BS

18. Use of Metformin in the Treatment of Patients with Congenital NDI (Nephrogenic Diabetes Insipidus)

Purpose: Nephrogenic diabetes insipidus (NDI) is a genetic disease. Patients with this disease make large amounts of urine because their kidneys don’t hold on to water. The large amount of urine means that patients need to urinate very frequently. They are also at increased risk for dehydration if they don’t drink enough. The large amount of urine can sometimes damage their bladders and kidneys. There are some medicines that may help these patients urinate less, but they are not very effective. There is evidence in animal studies that a medication called metformin may help patients with NDI urinate less. Metformin is a medication currently used to treat patients with diabetes and other conditions. We are going to test metformin in patients with NDI. Patients will be invited to the Emory Clinical Research Center for a baseline urine measurement. They will return home and stop their usual medicines to treat NDI. Then another 24 hour urine collection which they will take to the nearest quest laboratory. Then they will resume metformin 500mg twice a day for 3 weeks. 24-hour urine will be collected once a week for 3 weeks in order to measure the volume of the urine and the urine concentration. After three weeks the medications will be discontinued.

Recruitment Status: Enrolling

Sponsor: Investigator Initiated

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Margo Kamel, PhD

19. An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients with Hyperphosphataemia

Purpose: This a Phase 3, Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients with Hyperphosphataemia. The aim of this Phase 3 clinical study is to demonstrate similar efficacy of PA21 (Velphoro) in paediatric and adolescent patients with CKD, and to provide safety and dosing information for this patient population. The Phoslyra (comparator) group provides information for a descriptive comparison of PA21 against a commonly used calcium-based phosphate binder (calcium acetate).

Recruitment Status: Enrolling

Sponsor: Vifor Fresenius Medical Care Renal Pharma

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Helina Iyob-Tessema, BS

20. Cystinosis: Clinical Outcomes in a Contemporary Group of American Patients

Purpose: We will be conducting a retrospective study to define the clinical outcomes of a contemporary group of nephropathic cystinosis patients in the United States.

Recruitment Status: Enrolling

Sponsor: Raptor Pharmaceuticals INC

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Study Coordinator: Margo Kamel, PhD

21. Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome

Purpose: This study is a multi-center registry that collects information on children with childhood nephrotic syndrome who have been treated with a drug called ACTHar. ACTHar use in children is limited so a data registry will help guide medical decisions in the future and will help to design future research studies.

Recruitment Status: Enrolling

Sponsor: North American Pediatric Transplant Case Study

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Margo Kamel, PhD

22. cNeptune (Children’s Nephrotic Syndrome Study Network)

Purpose: In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium. Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.

Recruitment Status: Enrolling

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Site PI: Dr. Larry Greenbaum, Director, Division of Pediatric Nephrology, Emory University, Atlanta, GA

Site Coordinator: Brian Lee, BS

23. Urological and Renal Disease Engaging Adolescents in Adherence Collaborative Trial (U-REAACT)

Purpose: The overarching goal of this five-year, phase II, randomized clinical trial is to improve poor long-term health outcomes in both adolescents and young adults (AYA) with either a kidney transplant (KT) or spina bifida (SB), respectively. More specifically, this study will focus on decreasing premature allograft loss in subjects with kidney transplant (KT) due to medication nonadherence and kidney damage in subjects with SB due to urinary non-continence. To achieve these goals, this study will implement a real-time feedback system, Way to Health (WTH), that will provide education and support, increase awareness and incentivize positive health behavior, in addition to standard of care. Further, this study will investigate the mechanisms of behavior change by examining the role of financial incentives, positive feedback and the relationship between the two. The study will compare two cohorts of KT and SB subjects, which will undergo varied levels of financial incentives and positive feedback. Data from KT and SB subjects will be analyzed jointly and separately. This innovative mobile health (mhealth) strategy will improve our current measures of adherence and increase our understanding of factors that influence adherence for two AYA populations, KT and SB subjects, respectively. The study will contribute novel insight to inform the design of future interventions targeting persistence of behavior change and can be used in other centers and for other chronic disease groups.

The study intervention will use the WTH web-based platform to support AYA with KT or SB as they navigate their daily treatment burdens. This will be achieved via bi-directional text messaging, including the sending of reminders and positive feedback by WTH and the messaging of pictures of medication or catheter in hand at time of treatment by the participant. This intervention will assess sustainability of this novel bi-directional messaging system and the impact of providing education and support, increasing awareness and incentivizing positive health behavior in real-time.

Recruitment Status: Planning Stage

Sponsor: National Institute of Health (NIH) and Children’s Hospital of Philadelphia (CHOP)

Site PI: Dr. Roshan George

Site Coordinator: Helina Iyob-Tessema, BS

24. A Phase 2/3 Trial of the the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome (CARDINAL)

Purpose: This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport syndrome. The Phase 2 portion of the trial will be open-label and enroll up to 30 patients. The Phase 3 portion of the trial will be double-blind, randomized, placebo-controlled and will enroll up to 180 patients.

Recruitment Status: Start Up Phase

Sponsor: Reata Pharmaceuticals

Site PI: Dr. Greenbaum

Site Coordinator: Brian Lee, BS

25. Study of Weekly RG-012 Injections in Patients with Alport Syndrome (HERA)

Purpose: This will be a randomized, double-blind, placebo-controlled, multi-center, Phase 2 study conducted in subjects with Alport syndrome at multiple investigative centers.

Recruitment Status: Planning

Sponsor: Regulus Therapeutics Inc.

Site PI: Dr. Greenbaum

Site Coordinator: Brian Lee, BS

26. ATHENA: Natural History of Disease Study in Alport Syndrome Patients

Purpose: There is limited published clinical data about the natural history of renal disease in Alport syndrome. The RG012-01 study will collect data to characterize the progression of renal dysfunction in Alport syndrome patients.

Patients with a confirmed diagnosis of Alport syndrome who have qualifying GFR will be considered for enrollment. The sequential sampling of subjects' urine and/or blood will allow an assessment of the rate of change of established clinical endpoints, such as GFR and/or the rate of change of other renal biomarkers (proteinuria and β-2 microglobulin) in subjects whose renal function is steadily declining. The identification of surrogate markers that track the decline of renal function and could correlate with time to end-stage renal disease (ESRD) is a key goal of the natural history study.

Recruitment Status: Planning

Sponsor: Regulus Therapeutics Inc.

Site PI: Dr. Greenbaum

Site Coordinator: Brian Lee, BS

Children's Healthcare of Atlanta

Pediatric Nephrology Team Members

& Our Emory Transplant Surgery and Pediatric Urology Colleagues

Pediatric Nephrologists

Larry Greenbaum, MD, PhD, Division Director

Barry Warshaw, MD, Fellowship Program Director

Donald L. Batisky, MD

Stephanie Jernigan, MD

Pamela Winterberg, MD

Rouba Garro, MD

Roshan P. George, MD, Assoc. Fellowship Program Dir.

H. Stella Shin, MD

Chia-shi Wang, MD

Sabina Kennedy, MD

Pediatric Nephrology Fellows

Loretta Reyes, MD – PGY-6

Karezhe Mersha, M.D. – PGY-5

K’Joy Simms, MD – PGY-5

Jackson Londeree, DO – PGY-4

Catherine Park, MD – PGY-4

Transplant Surgeons

Christian Larsen, MD, PhD

Thomas Pearson, MD, PhD

Kenneth Newell, MD, PhD

Paul Tso, MD

Nicole Turgeon, MD

Andrew Adams, MD, PhD

Ronald Parsons, MD

Idelberto “Raul” Badell, MD

William Kitchens, MD, PhD

Denise Lo, MD

Joseph Magliocca, MD

Raymond Lynch, MD, MS

Transplant Surgical Fellows

Douglas Anderson, MD

Austin Schenk, MD, PhD

Jakub Woloszyn, MD, PhD

Renal Transplant Coordinators

Camille Echols, BSN

Debbie Stearns, BSN, CCTC

Kidney Transplant Ped. Nurse Practitioner

Rachel Mullis, DSN, PNP

Chronic Renal Insufficiency Care Coordinators

Lynne Miles, BSN

Hypertension Care Coordinator

Rhodina Jones, BSN, CPN

Nephrology Nurse Practitioner

Lindsay Armstrong, RN, CPNP

Transplant Pharmacist

Rochelle Liverman, Pharm.D.

Staci Glumova, Pharm. D.

Nephrology Child Life Specialist

Ellie Armstrong

Nephrology Office Nurses

Vernon Griffith, LPN

Toni-Marie Partridge, RN

Carolyn Mitchell, RN

Lisa Palm, RN, MS

Nephrology Office Administrative Assistant

Alicia Boswell

Elizabeth (Liz) Shuler

Nephrology Fellowship Program Coordinator

Mary Jane Polizzotto, BBA

Research Coordinators

Margret Kamel, PhD, MSPH, CCRC

Brian Lee, BS

Helina Iyob-Tessema, BS

Segun Adgeabo, BS

Transplant Services Administrator

Laura Williams, RN

Transplant Services, CKD and HTN Manager

Lynn Sherrer, BSN, MN, PNP

Transplant Program Data Coordinator

Charlene Harris, BBA

Transplant Psychologist

Gloria Chaing, PhD


Melissa Connor

Christine Benedetti

Pediatric Urology Colleagues

Emily Blum, MD

Wolfgang Cerwinka, MD

James Elmore, MD

Michael Louis Garcia-Roig, MD

Andrew Kirsch, MD

Hal Scherz, MD

Edwin Smith, MD

Pediatric Urology Fellows

Michelle A. Lightfoot, MD

Aylin Bilgutay, MD

Transplant Social Worker

David Cooper, MSW, LCSW

CKD Clinic Social Worker

David Cooper, MSW, LCSW

Transplant Services Educator

Dawn Johnson, BSN, RN,CPN,CCTN

Outpatient Educator – Jennifer Ellison, RN

Atlanta, Georgia is a diverse, cosmopolitan, hospitable, tree-filled city of over 5 million people with seasonal climate suitable for nearly year-round outdoor activities. A major transportation hub, the city has long maintained a steady growth in both population and cultural diversity. While cost of living is lower than many other major cities, entertainment options are vast including college and professional sports, arts, museums, theaters, shopping, symphony, the world's largest aquarium, and innumerable restaurant options, including a wealth of ethnic cuisines.

The weather in Atlanta is mild, with average temperatures ranging in the 40's in winter to the 80's in summer. Winter may occasionally bring a light snow, and summer water activities can be comfortably enjoyed from May through September. The average annual rainfall in the Atlanta area is 48 inches.

Centennial Olympic Park

Atlanta offers a wide range of outdoor recreational activities. Nearby lakes and rivers provide opportunities for fishing and swimming and just north of the city lie beautiful mountains that frequently draw those seeking trails for hiking and sites for camping. Atlanta is but a few hours away from the coastal communities and resorts of Georgia, Florida, South Carolina and Alabama.

Cultural activities in the city include a variety of theatres, art museums, symphonies, and historic sites such as the Carter Library and the Martin Luther King, Jr. Memorial. For the kid at heart, amusement parks, the Georgia Aquarium and Zoo Atlanta offer superb entertainment choices. The number of performing arts venues are almost too many to count. Atlanta is a sports lover's paradise, with competitive college athletics featured throughout the city and with the College Football Hall of Fame having recently relocated here. The city often hosts major sporting events such as the annual Southeastern Conference (SEC) football championship, the 2013 National Collegiate Athletic Association (NCAA) Men's Basketball Final Four competition and the 2013 NCAA Football Chick-Fil-A Bowl. Atlanta also offers a full range of enjoyable professional sports entertainment and venues with baseball, basketball, football and soon-to-be major league soccer teams each attracting loyal followings.

Atlanta truly is a place for everyone. It is a thriving, livable metroplex that strives to provide a comfortable, yet exciting place to call home.

Some Atlanta Links

Atlanta in 500 Words
Cost of Living Calculator

About Atlanta
Access Atlanta
Atlanta Journal-Constitution
City of Atlanta

Atlanta Botanical Gardens
CNN Studio
Georgia Aquarium
Georgia State Parks & Historic Sites
Jimmy Carter Center
Martin Luther King, Jr. National Historic Site
Six Flags over Georgia
Six Flags White Water
Stone Mountain Park
World of Coca-Cola
Zoo Atlanta
Center for Civil and Human Rights
Atlanta History Center
College Football Hall of Fame

Atlanta Braves
Atlanta Falcons 
Atlanta Golfer 
Atlanta Hawks 
Atlanta Motor Speedway 

High Museum of Art
Atlanta Ballet
Atlanta Symphony
Alliance Theater

Other Places of Interest:
Ponce City Market
Krog Street Market

Children's Healthcare of Atlanta, in collaboration with Emory University School of Medicine, offers three-year fellowships in pediatric nephrology to qualified, promising physicians. For more information please visit the CHOA Pediatric Nephrology Fellowship website.

Sudeshna Bandyopadhyay, MD. Director of Pathology Residency Training Program

Dept of Pathology

Wayne State University School of Medicine

540 E. Canfield

Detroit, MI 48201

Tel: (313) 577-2752 Fax: (313) 577-0057


Anatomic and Clinical Pathology Residency ProgramEdit

Number of residents (per year / total):

Visas Sponsored:


Excellent AP exposure, high AP board pass rate is result, good lectures in the morning, graduating residents get into highly-regarded fellowships


AP focused. CP needs an improvement

Work load:

Are you allowed to do external rotations?

  • Yes, if not already available in our institution

Famous Faculty: Dr. Vinod Shidham, Dr. Suzanne Jacques, Dr. William Kupsky and Dr. Wael Sakr

Do you feel you have:

Adequate preview time? yes

  • Sometimes we don't but most of the time it's ok

Adequate support staff (P.A.’s, secretarial, etc.)? PA's are knowledgeable but can be difficult to work with, secretaries are friendly

Adequate AP Teaching?

  • Yes – dedicated AP didactics

Adequate CP Teaching?

  • Yes – dedicated AP didactics except in CC

Please send application to

Cytopathology FellowshipEdit

Position Available: Two fellowships each year

Requirements: Candidates must be board eligible or certified in anatomic pathology or anatomic and clinical pathology, and be eligible for Michigan license.

Applications: Should be completed by August 1 of the preceding year. Send CV, personal statement, and three reference letters to: Vinod Shidham, M.D., Director of Cytopathology Fellowship Program ( and cc Kathy Rost, Program Coordinator (

Hematopathology FellowshipEdit

Positions Available: Two fellowships per year

Requirements: Candidates must be Board certified or eligible by the American Board of Pathology in AP/CP, and eligible for Michigan medical license.

Application: Send CV, three reference letters, and personal statement to:

Ali Gabali, MD, PhD, Fellowship Director ( and cc Pam Nelson, Program Coordinator (

Pediatric Anatomic Pathology FellowshipEdit

Position Available: One fellowship per year

Requirements: Candidates must be Board certified or eligible by the American Board of Pathology in AP or AP/CP, and eligible for a Michigan medical license. Application: Send CV, three letters of reference, and personal statement to:

Janet Poulik, M.D., Fellowship Director ( and cc Maggie Klein, Program Coordinator (

Surgical Pathology FellowshipEdit

Position Available: One fellowship per year

Requirements: Candidate must be Board certified or eligible by the American Board of Pathology in AP or AP/CP, and eligible for a Michigan medical license. Application: Send CV, three reference letters, and personal statement to:

Rouba Ali-Fehmi, M.D., Fellowship Director ( and cc Pam Nelson, Program Coordinator (

Categories: 1

0 Replies to “Rouba Residency Personal Statement”

Leave a comment

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *